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Abstract
LSD1, a lysine-specific histone demethylase, is overexpressed in several types of cancers
and linked to poor outcomes. In breast cancer, the significance of LSD1 overexpression is not
clear. We have performed an in silico analysis to assess the relationship of LSD1 expression
to clinical outcome. We demonstrate that LSD1 overexpression is a poor prognostic factor in
breast cancer, especially in basal-like breast cancer, a subtype of breast cancer with aggres-
sive clinical features. This link is also observed in samples of triple negative breast cancer. In-
terestingly, we note that overexpression of LSD1 correlates with down-regulation of BRCA1 in
triple negative breast cancer. This phenomenon is also observed in in vitromodels of basal-
like breast cancer, and is associated with an increased sensitivity to PARP inhibitors. We pro-
pose therefore that high expression levels of the demethylase LSD1 is a potential prognostic
factor of poor outcome in basal-like breast cancer, and that PARP inhibition may be a thera-
peutic strategy of interest in this poor prognostic subtype with overexpression of LSD1.
Introduction
LSD1, lysine specific demethylase 1, removes methyl groups from lysine residues of histone
H3, thereby regulating gene expression [1]. For gene repression, LSD1 removes mono- and di-
methyl groups from lysine 4 of histone H3 (H3K4) [1]. For gene activation, LSD1 works with
androgen/estrogen receptor to remove mono- and dimethyl groups from lysine 9 of histone
H3 (H3K9) [2,3]. The control of gene expression by LSD1 has been shown to be vital to multi-
ple processes including organogenesis and stem cell differentiation [4],[5]. In intracellular
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processes, it has been suggested that LSD1 promotes cell proliferation, survival and epithelial-
mesenchymal transition (EMT) [6]. LSD1 is often overexpressed in malignancies and it is
linked to poor clinical outcome in cancers of the lung, liver, colon and esophagus [7–10]. Over-
expression of LSD1 has been reported in estrogen receptor negative breast cancer, however it is
not known whether LSD1 is a prognostic factor of poor outcome in breast cancer [11].
Breast cancer has been classified into four subtypes based on gene expression profile [12].
Basal-like breast cancer, one of the subtypes, does not display hormonal receptors and human
epidermal growth factor receptor 2, HER2, suggesting resistance to hormonal therapy and HER2
antagonism [13]. These tumors display an aggressive clinical course, with high relapse rates [13],
and are an important area for the development of new therapeutic strategies. Loss of BRCA1, a
familial breast cancer susceptible gene, through mutation or epigenetic dysregulation often leads
to tumors with a basal-like phenotype [14]. Recent work has implicated LSD1 in this dysregula-
tion of BRCA1 [6]. Wnt signaling is upregulated in basal-like breast cancer, leading to accumula-
tion of the transcriptional repressor Slug (Snail2) [6]. The accumulated transcription repressor
targets LSD1 to promoter region of BRCA1 leading to its downregulation [6]. Thus LSD1may
play a critical role in acquiring poor prognostic phenotype in breast, but the relationship between
expression of LSD1 and the clinical outcome has not been demonstrated to date.
Using bioinformatics tools, we predict that LSD1 expression is linked to poor recurrence
free survival of patients with breast cancer, especially in the basal-like breast cancer. We have
also investigated the relationship between LSD1 expression and recurrence free survival in
32 samples of triple negative breast cancer and found that LSD1 is a prognostic factor of poor
clinical outcome. Furthermore, we have shown that LSD1 overexpression is linked to BRCA1
suppression. Therefore, we propose that PARP inhibitors, a novel class of targeted agents with
promising activity in BRCAmutant tumors, may be effective therapy for basal-like breast can-
cers with amplified LSD1 [15].
Materials and Methods
1.1. Bioinformatic analysis
Gene count data from Breast invasive carcinoma TCGA samples (RNA sequencing) were
downloaded from TCGA data portal. PAM50 definitions of intrinsic subtype were used to clas-
sify breast cancer into subtypes including basal-like, luminal A, luminal B and HER2 enriched
cohorts. The quantitation of mRNA expression was performed using All Complete Tumors of
Breast invasive carcinoma (TCGA, Nature 2012) dataset [16]. For the analysis of gene expres-
sion, raw counts were normalized by Trimmed Mean of M-values (TMM) using the R package
“edgeR” and “calcNormFactors” command. For survival analysis, a set of CEL files (GSE1456)
were downloaded from GEO database and normalized by MAS5.0 global mean method. Probe
set-based signal intensities were natural log transformed and scaled by adjusting the mean in-
tensity to a target signal value of log500. For survival analysis using KMplot, the data was ob-
tained from kmplot (www.kmplot.com) [17].
1.2. Statistical Analysis
Differential mRNA expression between two or more groups was analyzed by edgeR. For surviv-
al analysis, Gehan-Breslow-Wilcoxon tests were performed, as well as cox proportional hazard
models. To compare gene expression of BRCA1 in cancer with high or low LSD1, the Mann
Whitney U test was performed. Difference were considered to be significant when the two-
tailed p-value was< 0.05. Gehan-Breslow-Wilcoxon tests and Mann-Whiney U test were per-
formed using Graphpad prism. Cox proportional hazard models were fitted using the coxph
function (located in the survival library in R).
LSD1 in Breast Cancer
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1.3. Study approval
This project was approved by the Clinical Ethics Committee of the St. Marianna University-ap-
proval number: 2297-i103, with a waiver of consent granted for the use of archival clinical sam-
ples from the St. Marianna University Department of Pathology.
1.4. Immunohistochemistry (IHC) and measurement of protein
expression
Paraffin tissue sections were cut onto coated slides (3μm) and deparaffinized by routine tech-
niques. Endogenous peroxidase activity was blocked with a 3%H2O2 in PBS for 5min. For LSD1
staining, the sections were incubated with an anti-LSD1 antibody for 60 min. For BRCA1 staining,
antigen retrieval was performed with Antigen Retrieval Solution (pH 9.0) (Nichirei bioscience) at
95°C in a steamer for 40min, followed by the sections were incubated with an anti-BRCA1 anti-
body for 60 min. Labeling was detected with the Histofine Simple Stain, MULTI (Nichirei Biosci-
ence), following the protocol suggested by the manufacturer, and all sections were counter stained
with hematoxylin. For measurement of protein expression, the percentage of positive cells was de-
termined by counting about 500 cells within five high-resolution fields. Immunohistochemical
staining (IHC score) was evaluated using the semi-quantitative Remmele scoring system [18],
which links the IHC staining intensity (SI) with the percentage of positive cells (PP) (Table 1).
High-LSD1 is defined as above average IHC score = 5.
1.5. Cell culture
MDA-MB-231 and MDA-MB-157 were cultured in L-15 medium supplemented with 10%
foetal bovine serum and 1% antibiotic-antimycotic agent at 37°C. HCC70 were cultured in
RPMI1640 medium supplemented with 10% foetal bovine serum and 1% antibiotic-antimyco-
tic agents at 37°C with 5% CO2.
1.6. Plasmids
A construct including cDNA of LSD1 was a kind gift from Dr. Atsushi Yokoyama [19]. The
cDNA of LSD1 was subcloned into pcDNA3-myc- vector.
1.7. Antibodies
The antibodies and dilution used in this study were: Anti-BRCA1 (07–434) antibody (Milli-
pore, 1:2000 for WB, 1:500 for IHC); Anti-Myc (9E10) antibody (Neomarker, 1μg/μl, 1:1000);
Table 1. Criteria of IHC scoring.
Score Criteria




Percentage of Positive Cells (PP) 0: no positive cells
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Anti-LSD1 (2139) antibody (Cell Signaling Technology, 1:1000); and anti-β-actin (AC-15)
antibodies (Sigma, 1:1000).
1.8. Western blots
MDA-MB-231 and MDA-MB-157 were transfected with Lipofectamin2000 transfection re-
agent. HCC70 was electroporated with Cell Line Nucleofector Kit V in Nucleofector (Lonza)
(2x106 cells, 2ug of DNA, program P-020). Western blots were done as described previously,
briefly 48 hours after transfection, cells were lysed with 0.5% NP-40 lysis buffer (50mM Tris-
HCl pH7.5, 150mMNaCl, 0.5% NP-40, 50mM NaF, 1mMDTT, 1mM Na3VO4, complete pro-
tease inhibitor cocktail (Roche) and 1mM PMSF) and resolved by SDS-PAGE [20].
1.9. Colony formation assay
Cells were transfected as described above. Twenty-four hours after transfection, cells were plat-
ed into 6-well plates at a density of 4000 cells per well. Different doses of Olaparib (a PARP in-
hibitor, AZD2281, KU-0059436) were added, and the plates were incubated at 37°C for a week.
Cells were fixed with 75% methanol in 25% acetic acid for 5 min, and the plates were dried.
Colonies were stained with Lillie's crystal violet (2 g crystal violet, 0.8 g ammonium oxalate in
100 ml of 80% ethanol) for 5 min and subsequently washed with water, dried, and measured by
ImageQuant LAS 4000 (GE healthcare).
Results
2.1. Increased expression of LSD1 transcripts is observed in basal-like
breast cancer.
In order to validate whether LSD1 is overexpressed in each intrinsic molecular subtypes of
breast cancer, we have analyzed LSD1mRNA expression data from The Cancer Genome Atlas
(TCGA). The data was statistically analyzed by edgeR [21] and the analysis indicates that
basal-like breast cancers show a significantly higher amount of LSD1 transcript than the other
subtypes. (p<0.0001) (Fig. 1 and Table 2). Although it is known that LSD1 is overexpressed in
ER-negative breast cancer, upregulation of LSD1 transcripts is not seen in HER2 type breast
cancer that is also ER-negative (Fig. 1) [11].
2.2. mRNA level of LSD1 is a prognostic factor in basal-like breast
cancer
Among the intrinsic subtypes of breast cancer, basal-like and HER2 type breast cancer display
the most aggressive clinical features, but still lack defined molecular prognostic factors [13].
LSD1 is an established prognostic factor of poor outcome in several types of malignancies [7]
[8] [9] [10]. In breast, the impact of LSD1 on prognosis is not known. As shown in Fig. 1, LSD1
expression status is altered only in basal-like breast cancer. This prompted us to investigate the
correlation between LSD1 level and the clinical outcome. We have analyzed a single large data-
set (n = 159) available in GEO of recurrence free survival (RFS) to evaluate whether LSD1
overexpression is a prognostic factor in each intrinsic subtype of breast cancer [22]. The analy-
sis indicates that cancer with high LSD1 transcripts shows a trend to shorter recurrence free
survival (RFS) in basal-like breast cancer with a hazard ratio (HR) of 4.314 (Fig. 2B). Interest-
ingly, high level of LSD1 transcripts is related to good prognosis in luminal A type breast can-
cer (HR = 0.1426) and poor prognosis in HER2 type breast cancer (HR = 7.551) (Fig. 2C). To
expand these analyses, we have also looked at recurrence free survival data available at KMplot
(www.kmplot.com) that contains large number of samples including the GEO dataset [17].
LSD1 in Breast Cancer
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The analysis indicates that cancer with high LSD1 transcripts shows a trend to shorter recur-
rence free survival (RFS) when all subtypes of breast cancer are pooled (P = 0.024) (S1A Fig.).
However, in basal-like breast cancer, there is a clearer link to poor outcome with a hazard ratio
of 1.39 (S1B Fig.). Thus, these results indicate that increased expression of LSD1 transcripts
could serve as a prognostic factor for poor outcome in basal-like breast cancer.
2.3. Protein level of LSD1 is a prognostic factor in triple negative breast
cancer
Breast cancers have traditionally been classified on the basis of immunohistochemical reactivity
to Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2. Tumors which lack reactiv-
ity to all these three markers are termed ‘triple negative’ breast cancer, which constitute a clini-
cally aggressive subset [23]. Molecular profiling has shown significant overlap between the
Fig 1. Overexpression of LSD1 is observed only in basal-like breast cancer. This is a plot of LSD1
expression from the TCGA dataset (expression of mRNA as log2 TMM-normalized raw counts in the y-axis)
plotted across different subtypes of breast cancer (x-axis). Significant differences in mRNA between intrinsic
subtypes were calculated using edgeR. The number of samples were as shown in the scatter plots. LSD1 is
amplified in basal-like breast cancer when compared to other subtypes, in this dataset.
doi:10.1371/journal.pone.0118002.g001
Table 2. mRNA expression of LSD1 in subtypes of breast cancer.
Subtypes p-value q-value
Basal-like vs Luminal A 7.10E-40 8.97E-39
Basal-like vs Luminal B 3.27E-16 2.40E-15
Basal-like vs HER2 9.12E-06 4.21E-05
Basal-like vs Luminal A vs Luminal B vs HER2 7.39E-38 7.21E-37
False discovery rate calculated by edgeR are also shown as q-value.
doi:10.1371/journal.pone.0118002.t002
LSD1 in Breast Cancer
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gene-expression based subtype ‘basal-like’ and the immunohistochemical ‘triple negative’ sub-
types of breast cancer [12] [24] [25]. To extend the results from our bioinformatic analysis, we
have checked the impact of expression of LSD1 protein product on prognosis in triple negative
breast cancer (TNBC), given the similarity in clinical features to basal-like breast cancer. For
this study, we used samples from 32 patients at St. Marianna University hospital with clinical
Fig 2. Overexpression of LSD1 is linked to poor outcome in basal-like breast cancer. Effect of LSD1 overexpression (as defined by scores>median)
on recurrence free survival (RFS) across all or for each subtype of breast cancer are shown (overall breast cancer, n = 159 (A), basal-like, n = 25 (B), luminal
A, n = 39 (C), luminal B, n = 23 (D) and HER2, n = 15 (E)). Overexpression of LSD1 transcripts shows significant shorter RFS in basal-like or HER2 type
breast cancer (p = 0.0309, p = 0.0329, respectively). P-value was calculated using Gehan-Breslow-Wilcoxon test.
doi:10.1371/journal.pone.0118002.g002
LSD1 in Breast Cancer
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information, diagnosed and treated between 2007 and 2011. The median follow-up period is
1279 days. The clinical information of the patients is shown in (Table 3). Eleven samples had
high level of LSD1 protein (IHC score> 5, see materials and methods), which correlate with
shorter recurrence free survival, showing a hazard ratio of 3.619 (Fig. 3A-C, Table 4). We have
also used the cox proportional hazard model to adjust for the effect of age. This analysis also
Table 3. Clinical information of triple negative breast cancer.
Average age 54.3 (28–83) 54 (median)
Chemotherapy Neo-adjuvant 21
Adjuvant 11










Fig 3. Overexpression of LSD1 is linked to poor outcome in triple negative breast cancer.Representative images of immunohistochemistry of LSD1 in
20 clinical samples are shown (A and B, LSD1 high and low, respectively). The Kaplan Meir curve compares the recurrence free survival of cancer with high
or low level LSD1 protein products (C). Definition of LSD1 high is samples that have IHC scores above 5.
doi:10.1371/journal.pone.0118002.g003
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shows that LSD1 is a prognostic factor of poor clinical outcome with a hazard ratio of 3.688
(Table 5). Thus, in TNBC, high expression of the protein product of LSD1 is a prognostic factor
of poor outcome, extending our observations on the link between LSD1 transcript levels and
outcome in basal-like breast cancer.
2.4. Overexpression of LSD1 suppresses BRCA1 expression and is
associated with sensitivity to PARP inhibition
Wnt signaling is upregulated in basal-like breast cancer [6]. Canonical Wnt signaling promotes
degradation of GSK-3β by ubiquitin-proteasome system, which in turn leads to accumulation
of Slug (Snail2). The accumulated Slug targets LSD1 to the promoter region of BRCA1 gene,


































IHC score are shown.
IHC score = SI*PP (see material and methods)
doi:10.1371/journal.pone.0118002.t004
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and subsequent suppression of BRCA1 expression via histone modification [6]. However it is
not known whether overexpression of LSD1 directly affects BRCA1 expression.
We therefore analyzed the relationship between BRCA1 and LSD1 protein level in our set of
triple negative breast cancer samples. Eleven cases exhibit high level of LSD1 (IHC score> 5)
and have significantly decreased expression level of BRCA1 in comparison to TNBC samples
with low/normal LSD1 levels (p = 0.0334) (Table 4 and Fig. 4A). We then tested the effect of ec-
topic expression of LSD1 in a set of 3 basal-like breast cancer cell lines. Overexpression of LSD1
suppresses endogenous expression of BRCA1 in all three cell lines we tested (Fig. 4B).
PARP inhibitors are a novel class of potent anti-cancer agents with specificity for cancers
with mutant BRCA genes, through a synthetic lethal relationship [26]. Further studies have re-
vealed that sensitivity to PARP inhibitor is predicted not only by mutations in the BRCA genes,
but also by low expression levels of the BRCA1 protein [15]. As shown in Fig. 4A-B and
Table 4, overexpression of LSD1 suppresses expression of BRCA1. Therefore we hypothesized
that basal-like breast cancer cells with overexpression of LSD1may be sensitive to PARP inhib-
itor via suppression of BRCA1. Accordingly, ectopic expression of LSD1 leads to an increased
sensitivity of basal-like breast cancer cells to PARP inhibition (Fig. 4C-E). Thus, we propose
that PARP inhibition may be a potential therapeutic strategy for basal-like breast cancer, espe-
cially in the poor prognosis subgroup as defined by overexpression of LSD1.
Discussion and Conclusions
We have investigated the impact of LSD1 expression on clinical outcome in a large data set of
breast cancer. We found that amplification of LSD1 is observed in basal-like breast cancer, and
is a prognostic factor of poor outcome in this subtype. We have also found that protein product
of LSD1 is a biomarker of poor outcome in triple negative breast cancer. There have been sever-
al studies attempting to develop methods to diagnose poor prognostic subgroups of triple nega-
tive and basal-like breast cancer, because of the poor clinical outcome associated with this
subtype despite aggressive chemotherapy in the adjuvant setting. The results shown here sug-
gest that LSD1 levels could potentially serve as such a marker. Since the work presented is
based on retrospective and in-vitro analyses, further prospective validation in clinical samples
is needed.
We have found that LSD1 overexpression suppresses levels of BRCA1 in our clinical sam-
ples of triple negative breast cancer, and that this effect is reproduced in in-vitromodels. Wnt
signaling has been reported to modulate the link between LSD1 and BRCA1 [6]. Wnt signaling
is upregulated in several types of cancer, and this may suggest that suppression of BRCA1 by
LSD1 could play a role in other type of cancers as well [27], where LSD1 overexpression has
been reported to be a prognostic factor of poor clinical outcome [7] [8] [9] [10]. Further studies
in-vitro and in-vivo will be required to confirm this.
Table 5. Cox proportional hazard model for clinical samples.
univariate adjusted
HR 95% C.I. p-value HR 95% C.I. p-value
LSD1 3.619 1.222–10.72 0.0203 3.688 1.232–11.040 0.0197
Age 1.002 0.966–1.032 0.912 1.005 0.962–1.029 0.7573
Age was evaluated as a continuous variable.
doi:10.1371/journal.pone.0118002.t005
LSD1 in Breast Cancer
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Fig 4. Overexpression of LSD1 reduces BRCA1 expression in triple negative or in basal-like breast cancer and increases sensitivity to PARP
inhibitor in basal-like breast cancer.Histogram shows protein expression of BRCA1 in triple negative breast cancer with high or low level of LSD1 protein
(A). Y-axis indicates IHC score of BRCA1. Basal-like breast cancer cell lines (MDA-MB-231, MDA-MB-157 and HCC70) was transfected as indicated. Cell
lysates were subjected for Western Blots with indicated antibodies (B). Cell viability of basal-like breast cancer cell lines are assessed by colony formation
assay. Percent survival is shown in different doses of PARP inhibitor. Error bars show standard deviation of three independent experiments (C-E).
doi:10.1371/journal.pone.0118002.g004
LSD1 in Breast Cancer
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Since it has been reported that suppression of BRCA1 sensitizes cells to PARP inhibitors, we
speculated that LSD1 overexpressing cancer cells would be sensitive to PARP inhibition [15].
As expected, indeed LSD1 overexpressing cancer cells were sensitive to this drug in vitro. Sub-
sequent validation of these findings in a larger clinical cohorts and cell line collections will be
required for development of this finding into a clinically applicable biomarker. Nonetheless,
our findings are the first to demonstrate that LSD1 is a prognostic factor in basal-like breast
cancer and PARP inhibition is a potentially an effective therapeutic strategy for this difficult to
treat subtype of cancer.
Supporting Information
S1 Fig. High-expression of LSD1 is linked to poor outcome in basal-like breast cancer. Ef-
fect of high LSD1 (as defined as values>median) on recurrence free survival (RFS) in all or in
specific subtypes of breast cancer are shown (overall breast cancer, n = 3180 (A), basal-like,
n = 540 (B), Lumina A, n = 1540 (C), Luminal B, n = 907 (D) and HER2, n = 193 (E)) using
pooled data from kmplot.org. High expression of LSD1 transcripts shows significant shorter
RFS in all or basal-like breast cancer (p = 0.0015, p = 0.0025, respectively). KMplot divides the
data into two groups based on LSD1 expression as compared to the median. P-value was calcu-
lated using Gehan-Breslow-Wilcoxon test.
(TIF)
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